Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DO NOT RELEASE | Other Identifier | CB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Michael J. Fox Foundation for Parkinson's Research | OTHER |
Not provided
Not provided
Not provided
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.
A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
This study will assess the efficacy of ketamine for the treatment of depression in Parkinson's disease (PD), in a parallel, double-blind, placebo controlled randomized clinical trial (RCT). Imaging will be used to examine the mechanistic effects of ketamine treatment. Specifically, the investigators will use positron emission tomography (PET) to measure synaptic density and functional magnetic resonance imaging (fMRI) to measure functional connectivity. The investigators hypothesize that a course of ketamine treatment will result in a significant reduction in depression severity compared to placebo. Mechanistically, ketamine will result in a reorganization of functional networks and an increase in synaptic density.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketamine Infusion | Experimental | Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry |
|
| Saline Infusion | Placebo Comparator | Participants will receive 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine Infusion | Drug | Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Depression Severity | The primary outcome of depression severity post-treatment will be compared between groups using a linear mixed model with group (ketamine, placebo) included as a between-subjects factor and time (baseline, weeks 1, 2, 3) included as a within-subjects factor. The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression. | Baseline, Week 1, Week 2, and Week 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Blood pressure: systolic | Changes in systolic and diastolic blood pressure determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in Blood pressure: diastolic |
Not provided
Inclusion Criteria:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Presence of Dementia and a Montreal Cognitive Assessment (MoCA) score of less than 18.
A primary psychiatric disorder (as determined by the MINI) except for MDD
Active suicidal ideation with intent
History of substance dependence in the last 2 years
Current substance use disorder, except tobacco use disorder
Prior clinical psychiatric treatment with ketamine or prior recreational use of ketamine
A history of or current significant medical (e.g. cardiovascular, renal), or neurological (e.g. cerebrovascular, seizure, traumatic brain injury) illness other than PD that is unstable and significantly increase their risk and/or might affect the study objectives, as determined by study physicians
Uncontrolled hypertension, defined as average blood pressure greater than or equal to 140 mmHg or an average diastolic blood pressure greater than or equal to 90 mmHg among those patients who have hypertension.
Orthostatic hypotension (OH) that presents with symptoms sustained longer than a few minutes (e.g., light-headedness, blurred vision, dizziness, weakness, fatigue) or with syncope. OH is defined by a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within 3 minutes of standing compared with blood pressure from the sitting position.
Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines.
Any condition or finding that in the judgement of the PI significantly increases risk or significantly reduces the likelihood of benefit from participation in the study.
For participation in the PET/fMRI only:
Prior radiation exposure for research purposes within such that participation in this study would place them over FDA limits for annual radiation exposure (5 rem per yr)
Contraindications to MRI scanning.
Presence of a bleeding disorder as determined by the PT/INR (Prothrombin time and international normalized ratio) test
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sophie E. Holmes, PhD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | United States |
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D003863 | Depression |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo - Saline Infusion | Other | Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry |
|
Changes in systolic and diastolic blood pressure determined as clinically significant by the Investigator |
| Baseline and up to 19 days after last administration of study intervention |
| Change in Heart rate | Changes in heart rate determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in Respiration | Changes in respiration determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in O2 saturation | Changes in O2 saturation determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in ECG | Changes in ECG indicating a cardiac event such as an arrhythmia or ischemia determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in CBC with differential | Changes in CBD with differential determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in complete metabolic panel | Changes in complete metabolic panel determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in TFTs | Changes in TFTs determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Change in routine urinalysis | Changes in routine urinalysis determined as clinically significant by the Investigator | Baseline and up to 19 days after last administration of study intervention |
| Adverse events | Assessed by CTCAE v5.0 and the abbreviated version of the SAFTEE-GI and -SI to assess all body systems | Baseline and up to 32 days after last administration of study intervention |
| Change in synaptic density | The change in synaptic (SV2A) density (measured using [11C]UCB-J PET) between baseline and post-intervention scans will be measured across regions of interest | Baseline, Week 3 |
| Change in network function | The change in network function will be measured by comparing fMRI functional connectivity between baseline and post-intervention scans | Baseline, Week 3 |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |